NASDAQ:CYTK
Cytokinetics Stock News
$48.51
-0.610 (-1.24%)
At Close: May 31, 2024
Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
07:30am, Friday, 26'th Feb 2021
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 28 it is joining the European Organisation for Rare Diseases
Cytokinetics, Inc. (CYTK) CEO Robert Blum on Q4 2020 Results - Earnings Call Transcript
02:19am, Friday, 26'th Feb 2021
Cytokinetics, Inc. (CYTK) CEO Robert Blum on Q4 2020 Results - Earnings Call Transcript
Cytokinetics Names Muna Bhanji to Board of Directors
07:30am, Thursday, 18'th Feb 2021
Appointment Adds to Board Expertise in Commercial Development and Market Access as Company Prepares for Further Corporate Development Appointment Adds to Board Expertise in Commercial Development and
Cytokinetics to Announce Fourth Quarter Results on February 25, 2021
04:00pm, Thursday, 11'th Feb 2021
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 25, 2021 at 4
Cytokinetics Announces Recipients of Third Annual Communications Fellowship Grants
07:30am, Tuesday, 02'nd Feb 2021
Total of $100,000 Awarded to Five Organizations to Support Communications and Community Outreach Total of $100,000 Awarded to Five Organizations to Support Communications and Community Outreach
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Monday, 01'st Feb 2021
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 29, 2021 it granted stock options to purchase an aggregate of 1
Cytokinetics Announces First Patient Dosed in Cohort 2 of Redwood-HCM
07:30am, Wednesday, 13'th Jan 2021
Company Earns $2.5 Million Milestone Payment from Ji Xing Pharmaceuticals Company Earns $2.5 Million Milestone Payment from Ji Xing Pharmaceuticals
Cytokinetics Granted Orphan Drug Designation for CK-3773274 for the Treatment of Hypertrophic Cardiomyopathy
07:30am, Monday, 11'th Jan 2021
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug design
Cytokinetics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
04:00pm, Wednesday, 06'th Jan 2021
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to par
Cytokinetics Regains European Rights to Omecamtiv Mecarbil
07:30am, Wednesday, 23'rd Dec 2020
Company is Planning Regulatory Interactions in 2021 to Discuss Results of GALACTIC-HF and Expects to Evaluate Strategic Options for Co-Commercialization and Licensing Company is Planning Regulatory In
Cytokinetics Announces Data and Trial Design Presented at the International Symposium on ALS/MND
07:30am, Monday, 14'th Dec 2020
Additional Data from FORTITUDE-ALS Support Rationale and Design for COURAGE-ALS, A Planned Phase 3 Clinical Trial of Reldesemtiv in Patients with ALS Additional Data from FORTITUDE-ALS Support Ration
Cytokinetics Announces Progression of REDWOOD-HCM to Cohort 2
07:30am, Wednesday, 09'th Dec 2020
Interim Analysis of Data from Cohort 1 Demonstrate Substantial Effects of CK-274 to Reduce LVOT Gradient in Patients with Obstructive Hypertrophic Cardiomyopathy with No Dose Interruptions Due to Left
Cytokinetics Announces Additional Results From GALACTIC-HF Presented at the 17th Global Cardiovascular Clinical Trialists
07:30am, Monday, 07'th Dec 2020
Supplemental Analyses of Primary Composite Endpoint Further Demonstrate Effect of Omecamtiv Mecarbil In Patie nts with Lower Ejection Fraction
Cytokinetics Announces Three Presentations at the International Symposium on ALS/MND
07:30am, Thursday, 03'rd Dec 2020
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three poster presentations at the 31st International Symposium on ALS/MND takin
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:00pm, Tuesday, 01'st Dec 2020
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 30, 2020 it granted stock options to purchase an aggregate of
